Last reviewed · How we verify
Myoinositol
At a glance
| Generic name | Myoinositol |
|---|---|
| Also known as | D-[U-13C], femtonex, Viocyst, myoinositol/d-chiro-inositol combination (MYO/DCI) in 40:1 ratio, cis-1,2,3,5-trans-4,6-cyclohexanehexol |
| Sponsor | University of Colorado, Denver |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Hypercholesterolemia
- Hypertriglyceridemia
- Hypoalphalipoproteinemia
- Mixed hyperlipidemia
- Myocardial Reinfarction Prevention
- Niacin deficiency
- Pellagra
- Slow Progression of Coronary Artery Disease
Common side effects
Key clinical trials
- Myo-Inositol for Infertility in PCOS (NA)
- Berberine Phytosome for Signs and Symptoms of Polycystic Ovary Syndrome (PCOS) (NA)
- A Clinical Trial Via Telepsychiatry of Treatments for the Management of Emotional Dysregulation in Youth (PHASE4)
- Study of the Effect of a Nutritional Supplement on Microbiota, Metabolic Control, Inflammatory Profile, and Quality of Life in Patients With Polycystic Ovary Syndrome. (NA)
- Metformin Versus Myo-inositol in the Management of Polycystic Ovarian Disease: A Comparative Study (PHASE1)
- Comparative Effect of Myo-inositol With That of D-chiro-inositol on Insulin Resistance in Infertile Women With Polycystic Ovary Syndrome (PCOS). (NA)
- Local Treatment of Breast Pain Based on the Daily Use of a Topical Gel (NA)
- Vitamin D, Epigallocatechin Gallate, D-chiro-inositol and Vitamin B6 in Uterine Fibroid (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |